Floatz logo

ly03017

Negative Symptoms of Schizophrenia

Luye Pharma Group Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

144 Active assets in the Negative Symptoms of Schizophrenia cohort.

Asset / SponsorPhaseRating
Lurasidone
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4BBB
Asenapine
Noven Pharmaceuticals, Inc.
Phase 4BBB
Xanomeline
European Group for Research In Schizophrenia
Phase 4BBB
TROSPIUM
European Group for Research In Schizophrenia
Phase 4BBB
Opc-34712
Humanis Saglık Anonim Sirketi
Phase 4BBB

View all 50 →

Same molecule, other indications

ly03017 is also rated in:

Parkinson Disease PsychosisDormant
CC
Indicative ·
43 / 100
View asset →
Alzheimer diseaseDormant
NR
Indicative ·
/ 100
View asset →
Parkinson diseaseDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →